Genelux Corporation reported second-quarter 2026 financial results and said topline data from the Phase 3 OnPrime/GOG-3076 registrational trial of Olvi-Vec in ovarian cancer are expected in the second half of 2026. The company also said systemic Olvi-Vec programs in lung cancer are advancing, with additional dose-escalation updates expected in 2026, and pointed to recently published Phase 1b/2 VIRO-15 translational analyses in heavily pre-treated ovarian cancer patients that support Olvi-Vec's potential to overcome resistance biology and work synergistically with platinum chemotherapy. In platinum-resistant/refractory ovarian cancer, OnPrime/GOG-3076 is comparing Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab with physician's choice of chemotherapy and bevacizumab. In lung cancer, Genelux is running a China-based Phase 1b/2 small-cell lung cancer study through licensing partner Newsoara HYK Biopharmaceuticals Co., Ltd. and a U.S.-based Phase 2 non-small-cell lung cancer trial that combines Olvi-Vec with platinum-based chemotherapy and an immune checkpoint inhibitor (ICI, a drug that helps the immune system attack cancer). Cash, cash equivalents, marketable securities and restricted cash were $18.7 million as of June 30, 2026, which the company said should fund operations into the first quarter of 2027. Research and development expenses rose to $6.5 million from $4.8 million a year earlier, general and administrative expenses were $3.1 million versus $3.0 million, and net loss widened to $9.5 million, or $0.21 per share, from $7.5 million, or $0.20 per share, in the same quarter of 2025.